Critères d'inclusion : - Patients with pathologically confirmed selected tumor types;
- Mandatory availability of adequate human biological material (HBM): at least one FFPE tissue sample or fresh bone marrow sample in the case of hematological malignancies, from either the primary tumor and/or recurrent tumor and/or metastasis, obtained from any adequate surgery or biopsy, as well as blood sample at baseline and follow up;
- Centrally performed confirmation of tumor tissue adequacy in terms of quality/ quantity for central screening;
- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule;
- Age ≥ 12 years;
- Written informed consent according to applicable legal and ethical requirements;